Navigation Links
Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
Date:12/14/2007

BALTIMORE, Dec. 14 /PRNewswire/ -- Alba Therapeutics Corporation announced today that it has entered into a strategic collaboration with Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), to jointly develop AT-1001, Alba's lead inhibitor of barrier dysfunction in various gastrointestinal ("GI") disorders. Shire will receive rights to commercialize all forms of AT-1001 outside of the United States and Japan. Alba will retain all rights to commercialize AT-1001 in the United States and Japan.

Under the terms of the collaboration, Alba will receive an initial, non- refundable licensing payment of US$ 25 million. Joint development costs toward global approval of AT-1001 will be shared 50/50 after the completion of two Phase 2 studies for Celiac disease. Alba is eligible to receive over US$ 80 million if certain clinical, regulatory and launch milestones are met for certain GI indications. Additional milestone payments totaling over US$ 40 million per indication will also be payable to Alba if the Collaboration is expanded beyond GI indications. Alba is also eligible to receive up to US$ 220 million in sales-based milestones, as well as tiered royalties. Not including royalties and cost sharing, the deal is valued at over US$ 325 million if all milestones are achieved.

Dr. Blake M. Paterson, Alba's President & CEO said:

"We are pleased to enter into this partnership with Shire, which leverages the unique experience and expertise of both companies in developing therapies for GI disorders. The combination of Alba's barrier function technology and autoimmune development capabilities with Shire's proven track record in GI drug development and commercialization will greatly enhance our efforts to bring these novel therapies to patients."

Matthew Emmens, Shire's CEO said:

"Alba's products have the potential to be an excellent addition to our current gastrointestinal business. This technology should provide significant benefit to patients w
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... Available spectra is similar for all ... cultivation of a wide range of plants. The ... proven patented and pending wide spectrum technology. The ... critical applications in contrast to growth spectra made ... have a large variety of differently sized and ...
(Date:8/29/2014)... 29, 2014  Pfenex Inc. (NYSE MKT: PFNX), ... of high-value and difficult to manufacture proteins including ... reported financial results for the second quarter ended ... completion of our initial public offering, we have ... product candidates, derived from our proprietary protein expression ...
(Date:8/29/2014)... 2014 Pittcon is pleased to announce ... Koichiro Matsuda, Horiba Scientific, have organized a session on ... JASIS , Asia’s largest analytical and scientific instruments ... Messe, Japan. , The four speakers in this ... Single Molecules to Single Cells” will present their use ...
(Date:8/29/2014)... Boston, MA (PRWEB) August 29, 2014 Due ... (FRC) last week, the Adult Stem Cell Technology Center, ... donations to support stem cell therapy research that might benefit ... adult stem cells for new stem cell technologies and therapeutic ... ALS Ice Bucket Challenge donors who wish not ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3
... A highly sensitive, easy-to-use,test that accurately detects bovine ... New Veterinary Product for Diagnostics in the annual,Animal ... was selected for its,excellence and innovation by an ... of animal sciences practitioners and,professionals. The award was ...
... - New Product Under Development for the Treatment ... European Countries DAIICHI SANKYO EUROPE GmbH has applied ... medication. It is a fixed combination,(CS-8663) of two substances, ... Amlodipin. When approved, the new combination for treatment ...
... Kerry Weems, and Panel ... Awareness Month, WASHINGTON, Oct. 1 AdvaMed 2007, the,inaugural ... service providers, investors and leading CEOs of,medical technology companies from ... 3. With more than 45 industry sponsors, 26 U.S. ...
Cached Biology Technology:BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards 2BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards 3DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin 2Inaugural Conference AdvaMed 2007 Kicks Off Today 2Inaugural Conference AdvaMed 2007 Kicks Off Today 3
(Date:8/29/2014)... over the last 120,000 years may have influenced ... researchers led by City College of New York ... metric called "phylogeographic endemism." , It quantifies the ... is restricted in geographical space. , Dr. Carnaval, ... researchers from institutions in Brazil, Australia and the ...
(Date:8/29/2014)... marine phytoplankton, such as the prolific bloomer Emiliania ... researchers have discovered. The finding contradicts the common view ... microbes depend on scarce supplies of thiamine in the ... to think about the ocean," says CIFAR Senior Fellow ... Journal paper with CIFAR fellows John Archibald ...
(Date:8/28/2014)... is now available from the Lady Bird Johnson Wildflower ... identifying harmful non-native plant, insect and other invasive species ... cause about $137 billion in economic and other damage ... native plants and more. , "By having streamlined tools ... species occur, we,re more likely to catch these threats ...
Breaking Biology News(10 mins):CCNY team defines new biodiversity metric 2Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Mobile app makes ID of harmful plants, insects in Texas a snap 2
... are hospitalized each year due to hyperemesis gravidarum (HG), an ... and often forces them to reluctantly terminate their pregnancies. ... grandmothers on either side of the family who have experienced ... be heightened, according to a new study led by researchers ...
... children reported more frequent intake of healthy foods such ... well as low-energy cheese and yoghurt compared with normal ... researchers at Telemark University College, Norway and the ... showed that: Overweight children drank ...
... of reef fish will enact punishment on the parasitic ... take a bite, even though their behavior offers no ... in Current Biology , a Cell Press publication, ... reef fish species well. In future attacks, blennies ...
Cached Biology News:Study shows extreme form of pregnancy-related morning sickness could be genetic 2Overweight children have different eating patterns than normal weight children 2To punish or not to punish: Lessons from reef fish and saber-tooth blennies 2To punish or not to punish: Lessons from reef fish and saber-tooth blennies 3
... covers can be used with ... covers for stacking of covered ... for use with automated systems ... and non-ridged, are available for ...
... made from an inert polymer with a unique ... 384 split septum caps for use with 384-well ... PCR when used in conjunction with screw or ... standard pipetting equipment 384 septum caps may ...
... Bionic Buffer is a unique ... and TAE (TRIS acetate-EDTA) electrophoresis buffers. ... runs, extremely rapid running times, and ... use in gel electrophoresis after dilution ...
The Mu-End™ Protein Truncation Kit provides a convenient method for generating a library of N-terminal and C-terminal protein deletions that can be expressed in E. coli....
Biology Products: